Marketed By
Natco
Pack of
120 tablet
Salt Composition
Sorafenib
Storage
Keep in cold place
Contact for Price
Sorafenat 200mg Tablet
Delivering To: —
All Substitutes
Overview
- Sorafenib 200mg Tablet is used to treat certain types of cancer (liver cancer, kidney cancer, and thyroid cancer).
- This tablet belongs to a class of medication known as a tyrosine kinase inhibitor.
- This medicine helps to stop the growth of cancerous cells.
- Take this medicine orally.
Indication
- Liver Cancer (Hepatocellular Carcinoma)
- Kidney Cancer (Renal Cell Carcinoma)
- Thyroid Cancer (Differentiated Thyroid Carcinoma)
Uses
- Liver Cancer (Hepatocellular Carcinoma)
- Kidney Cancer (Renal Cell Carcinoma)
- Thyroid Cancer (Differentiated Thyroid Carcinoma)
Side Effects
Sorafenib 200mg Tablet may cause certain side effects. Make sure to contact your healthcare professional if side effects occur after administration or last longer than usual.
- Diarrhea
- Hand-foot skin reaction (painful blisters)
- Fatigue
- Hair loss
- Weight loss
- Rash
- Abdominal pain
- Nausea
- Loss of appetite
- Hypertension
Dosage and Administration
Take Sorafenib 200mg Tablet orally on an empty stomach once a day. Try not to miss your regular dosing schedule. Take this medicine as prescribed by your medical advisor. Do not crush or chew the tablet. The dose is decided by a medical advisor according to your response to the treatment and your previous medical condition. Regular monitoring of blood pressure is required during treatment with this medicine. Keep yourself hydrated and maintain good nutrition while taking this medicine.
Mechanism of action
- Sorafenat is a kinase inhibitor that decreases tumor cell proliferation in vitro.
- Sorafenat inhibited the tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice.
- Reductions in tumor angiogenesis were seen in models of HCC and RCC upon Sorafenat treatment, and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC.
Safety Advice
Alcohol
UNSAFE
Pregnancy
CONSULT YOUR DOCTOR
Breast Feeding
CONSULT YOUR DOCTOR
Driving
UNSAFE
Kidney
CONSULT YOUR DOCTOR
Liver
CONSULT YOUR DOCTOR
Missed Doses
It is advisable not to miss a dose. If you miss a scheduled dose of the Sorafenat tablet, contact your doctor immediately.
FAQs
This medication is used to treat a certain type of cancer (liver cancer, kidney cancer, and thyroid cancer). This tablet belongs to a class of medication known as a tyrosine kinase inhibitor. This medicine helps to stop the growth of cancerous cells.
Those who have squamous cell lung cancer, are allergic to any of its chemicals, or are currently taking carboplatin and paclitaxel are not advised to use Sorafenat 200mg Tablet.
Sorafenat 200mg Tablet works by blocking the action of a protein that signals the cancer cells to multiply. This helps in slowing down the growth of cancer cells.
Some common side effects of this medicine are nausea, irregular fatigue, diarrhea, nausea, hair loss, weight loss, rash, and hand-foot skin reaction (painful blisters).
This medicine may decrease your ability to drive or affect your vision. Do not drive if any symptoms occur.
Yes, people with diabetes can safely consume 200 mg tablets of sorafenat. Only take it after consulting a physician, though, as they may alter the dosage depending on the patient's health.
Take this medicine on an empty stomach orally once a day or as advised by the doctor.
References
- Pharmacokinetic and pharmacodynamic characteristics of sorafenib 200mg film‑coated tablets (sorafenat). (n.d.). Absorption, metabolism, and elimination profiles. medthority.com and PMC article summary.
- Study 100554 (SHARP trial) and Study 11849: sorafenib versus placebo in hepatocellular carcinoma and renal cell carcinoma. (n.d.). Summary of product characteristics and pivotal trial data publications. medicines.org.uk [SmPC & EMA summary].
- Suk, F. M., Wu, C. Y., Fang, C. C., Chen, T. L., & Liao, Y. J. (2023, August 9). β‑HB treatment reverses sorafenib resistance by shifting glycolysis‑lactate metabolism in HCC. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2023.115293
- TARGET Phase III trial: sorafenib in advanced renal cell carcinoma. (n.d.). Trial summary data reporting median PFS, OS, and hazard ratios. medicines.org.uk [SmPC & EMA summary].
Ratings And Reviews
4.71/5
7 Ratings
5 Star
71.43%
4 Star
28.57%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
Sophia Lopez
Highly recommended
a year ago
Charlotte Taylor
Will definitely order again
a year ago
View All Reviews
Related Products
MARKETER DETAILS
Natco
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.